Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab

BACKGROUND: The safety of pembrolizumab monotherapy in treatment‐naïve non‐small cell lung cancer (NSCLC) patients with high programed death‐ligand 1 (PD‐L1) expression and pre‐existing interstitial lung disease (ILD) has not yet been determined. Here, we aimed to evaluate the prognosis, efficacy an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Yamaguchi, Ou, Kaira, Kyoichi, Shinomiya, Shun, Mouri, Atsuto, Hashimoto, Kosuke, Shiono, Ayako, Miura, Yu, Akagami, Tomoe, Imai, Hisao, Kobayashi, Kunihiko, Kagamu, Hiroshi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7862785/
https://ncbi.nlm.nih.gov/pubmed/33185333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13725
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados